Neoadjuvant chemo affects PSA levels post-RP, but histology is unchanged

Weekly neoadjuvant chemotherapy with docetaxel (Taxotere) achieved aPSA response in almost 80% of a small group of high-risk prostate cancerpatients enrolled in a feasibility study of single-agent therapy.

Related Videos

Related Content

Advertisement

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 13th 2025

STOPCAP: ARPIs benefit younger patients with mHSPC

Benjamin P. Saylor

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 12th 2025

UGN-101 associated with favorable long-term durability in low-grade UTUC

Hannah Clarke

The median duration of response was 47.8 months among patients who achieved an initial complete response.

February 12th 2025

Mevrometostat/enzalutamide combo shows rPFS benefit in mCRPC

Benjamin P. Saylor

The treatment combination was associated with median radiographic progression-free survival of 14.3 months vs 6.2 months with enzalutamide alone.

Related Content

Advertisement

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 13th 2025

STOPCAP: ARPIs benefit younger patients with mHSPC

Benjamin P. Saylor

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 12th 2025

UGN-101 associated with favorable long-term durability in low-grade UTUC

Hannah Clarke

The median duration of response was 47.8 months among patients who achieved an initial complete response.

February 12th 2025

Mevrometostat/enzalutamide combo shows rPFS benefit in mCRPC

Benjamin P. Saylor

The treatment combination was associated with median radiographic progression-free survival of 14.3 months vs 6.2 months with enzalutamide alone.